Novartis’ Big Buy, Q3 Earnings, Regeneron’s Dropped Cell Therapy, More
Novartis started the week early with a Sunday afternoon announcement of the acquisition of neuromuscular drug developer Avidity Biosciences for $12B. That’s the second biggest buy of the year after Johnson & Johnson’s January acquisition of Intra-Cellular. The Avidity buy could read through positiv…
Transformative Shifts: Rare Diseases, IPOs, and GLP-1 Innovations
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events reshaping the industry landscape, from regulatory advancements to scientific breakthroughs and strategic bu…
Own the Role You Have: Novartis CEO Vas Narasimhan
Vas Narasimhan never planned on becoming a CEO. In fact, he says the idea only hit him six months before he got the Novartis job.
He credits his rise to a lesson from his parents: throw yourself fully into whatever you’re doing, because you never know what comes next.
Narasimhan talks through the s…
FBF | Vas Narasimhan & Steven Baert: The CEO & The Chief People and Organization Officer Perspective
Vas Narasimhan, the Novartis CEO and Steven Baert, Novartis’ Ex-Chief People and Organization Officer join the authors of The Curious Advantage Simon Brown, Paul Ashcroft and Garrick Jones, to discuss the importance of Curiosity in Business. They talk about how Novartis has worked to ‘unleash the …
Vas Narasimhan-Anthropic Appointment
Anthropic appointed Vas Narasimhan to its board on April 14, 2026, making him the first pharmaceutical industry executive to join the AI startup’s governing body. Critically, he was appointed by the Anthropic Long-Term Benefit Trust an independent body whose members have no financial stake in Anthr…
11AM Hour: President Trump Meets with the President of Lebanon, Novartis CEO on Earnings & Alphabet's AI Lineup 7/21/26
Novartis CEO Vas Narasimhan joins to break down the company's latest earnings report as they return to sales growth. Then, we bring you comments from President Trump as he meets with the President of Lebanon at the White House. Plus, we break down the details of Alphabet's three new Gemini models i…
Bonus: Advice to young people
In this special episode of In Good Company, Nicolai Tangen revisits the question he asks all his guests – what's your advice to young people? McLaren Racing's Zak Brown explains why you need mentors at every stage. Novartis CEO Vas Narasimhan reflects on a career that rarely went to plan. Investor …
11AM Hour: Exclusive Interviews with the CEOs of Biogen, Novartis & Visa 9/9/26
Biogen CEO Christopher Viehbacher joins from the Wells Fargo Health Care Conference to discuss the company's drug pipeline and growth outlook. Then, Novartis CEO Vas Narasimhan joins after the company had its third drug trial setback in a week. Plus, we bring you an interview with the CEO of Visa a…
Theo on A.I. · July 4th
From storyflo. This is your daily audio brief for July 4th. Quick one from Theo — five tech stories from overnight, ordered by how much they made me sit up. Let's get into it. First, from The Decoder. Anthropic launches its own drug discovery programs to tackle diseases Big Pharma considers unprofi…
Anthropic’s Board Structure-What Does it Mean for Compliance
The award winning, Compliance into the Weeds is the only weekly podcast which takes a deep dive into a compliance related topic, literally going into the weeds to more fully explore a subject. Looking for some hard-hitting insights on compliance? Look no further than Compliance into the Weeds! In t…
MESIN PENCARI PODCAST
Anda dapat menggunakan situs web kami untuk mencari podcast3,829,336dan episode196,563,750menurut orang, tempat, atau topik.
If I have seen further than others, it is by listening to podcasts and standing upon the shoulders of
giants.
‐ Isaac "Llamacorn" Newton
Sunting
Terima kasih telah membantu agar basis data podcast tetap terbaru
